AP23 G 1030 Bilancios

Taking responsibility seriously

Angelini Pharma presents its first Sustainability Report, a document in which the company accounts for its social, environmental, and economic performance, demonstrating a consistent commitment to establishing an open and constructive dialogue with stakeholders with whom it operates on a daily basis. The voluntary reporting, for the fiscal year 2022, follows international standards such as the Universal GRI Standards and aligns with the guidelines of the Corporate Sustainability Reporting Directive (CSRD) for defining "materiality."

In line with the purpose and vision of the Angelini Industries Group - taking care of people and building a better future together - the report delves into projects and key business activities that reflect the commitment to improving the quality of life for individuals, families, and communities, both in Italy and abroad.

This inaugural Sustainability Report marks a significant step in Angelini Pharma's journey towards integrating ESG factors into its management and corporate governance systems, actively contributing to the Sustainable Development Goals of the United Nations' Agenda 2030.

The company's sensitivity to social issues, inspired by the Ethical Code, has always been implicit in the identity, mission, and values of Angelini Pharma, which has dedicated itself to the health of individuals and the well-being of the community for over a century. The decision to undertake a sustainability reporting process, involving constant monitoring of the effects of corporate actions on society and the environment, as well as the risks and opportunities associated with ESG factors, will enable Angelini Pharma to pursue a continuous improvement process in ESG-related areas.

"One of the goals that I have set myself as part of my mandate is integrating sustainability into our business approach, transforming it into a competitive lever that - much like the competitiveness sparked by innovation and organization - is able to drive the rapid acceleration of Angelini Pharma‛s development. I am firmly committed to continue improving our work, monitoring the effects of our actions on people and the environment, and maintaining an open and constructive dialogue with you all. I have no doubt that as you leaf through the pages of this report you will gain a greater understanding and appreciation of an organization that, for over one hundred years, has striven to protect the health and improve the wellbeing of our countries", says Jacopo Andreose, Chief Executive Officer of Angelini Pharma.